Michael Papanicolaou

Michael Papanicolaou

Auto-generated profile, based on publicly available information

Michael Papanicolaou

10Department of Pathology, Stanford University School of Medicine, Stanford, California

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMichael Papanicolaou
Michael Papanicolaou
APAmelia L. Parker
Amelia L. Parker
MYMichelle Yam
Michelle Yam
EFElysse C. Filipe
Elysse C. Filipe
SWSunny Z. Wu
Sunny Z. Wu
TCThomas R. Cox
Thomas R. Cox
The tumour stroma, and in particular the extracellular matrix (ECM), is a salient feature of solid tumours that plays a crucial role in shaping their progression. Many desmoplastic tumours including breast cancer involve the significant accumulation of type I collagen. However, recently it has become clear that the precise distribution and organisation of matrix molecules such as collagen I is equally as important in the tumour as their abundance. Cancer-associated fibroblasts (CAFs) coexist within breast cancer tissues and play both pro- and anti-tumourigenic roles through remodelling the ECM. Here, using temporal proteomic profiling of decellularized tumours, we interrogate the evolving matrisome during breast cancer progression. We identify 4 key matrisomal clusters, and pinpoint collagen type XII as a critical component that regulates collagen type I organisation. Through combining our proteomics with single-cell transcriptomics, and genetic manipulation models, we show how CAF-secreted collagen XII alters collagen I organisation to create a pro-invasive microenvironment supporting metastatic dissemination. Finally, we show in patient cohorts that collagen XII may represent an indicator of breast cancer patients at high risk of metastatic relapse.

28 August 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
JCJessica Chitty
Jessica Chitty
MYMichelle Yam
Michelle Yam
LPLara Perryman
Lara Perryman
APAmelia L. Parker
Amelia L. Parker
JSJoanna N. Skhinas
Joanna N. Skhinas
TCThomas R. Cox
Thomas R. Cox
The lysyl oxidase family represents a promising target in stromal targeting of solid tumors due to the importance of this family in crosslinking and stabilizing fibrillar collagens and its known role in tumor desmoplasia. Using small-molecule drug-design approaches, we generated and validated PXS-5505, a first-in-class highly selective and potent pan-lysyl oxidase inhibitor. We demonstrate in vitro and in vivo that pan-lysyl oxidase inhibition decreases chemotherapy-induced pancreatic tumor desmoplasia and stiffness, reduces cancer cell invasion and metastasis, improves tumor perfusion and enhances the efficacy of chemotherapy in the autochthonous genetically engineered KPC model, while also demonstrating antifibrotic effects in human patient-derived xenograft models of pancreatic cancer. PXS-5505 is orally bioavailable, safe and effective at inhibiting lysyl oxidase activity in tissues. Our findings present the rationale for progression of a pan-lysyl oxidase inhibitor aimed at eliciting a reduction in stromal matrix to potentiate chemotherapy in pancreatic ductal adenocarcinoma.

5 July 2024 in Science Advances
Verified
Journal Article
Open access
BPBrooke Pereira
Brooke Pereira
SRShona Ritchie
Shona Ritchie
CCCecilia R. Chambers
Cecilia R. Chambers
KGKatie A. Gordon
Katie A. Gordon
AMAstrid Magenau
Astrid Magenau
PTPaul Timpson
Paul Timpson
Pancreatic ductal adenocarcinoma (PDAC) is characterized by increasing fibrosis, which can enhance tumor progression and spread. Here, we undertook an unbiased temporal assessment of the matrisome of the highly metastatic KPC ( Pdx1-Cre , LSL-Kras G12D/+ , LSL-Trp53 R172H/+ ) and poorly metastatic KP fl C ( Pdx1-Cre , LSL-Kras G12D/+ , Trp53 fl/+ ) genetically engineered mouse models of pancreatic cancer using mass spectrometry proteomics. Our assessment at early-, mid-, and late-stage disease reveals an increased abundance of nidogen-2 (NID2) in the KPC model compared to KP fl C, with further validation showing that NID2 is primarily expressed by cancer-associated fibroblasts (CAFs). Using biomechanical assessments, second harmonic generation imaging, and birefringence analysis, we show that NID2 reduction by CRISPR interference (CRISPRi) in CAFs reduces stiffness and matrix remodeling in three-dimensional models, leading to impaired cancer cell invasion. Intravital imaging revealed improved vascular patency in live NID2-depleted tumors, with enhanced response to gemcitabine/Abraxane. In orthotopic models, NID2 CRISPRi tumors had less liver metastasis and increased survival, highlighting NID2 as a potential PDAC cotarget.

11 March 2023 in Advances in Cancer Biology - Metastasis
Verified
Journal Article
Open access
SWSamuel S. Widodo
Samuel S. Widodo
Marija DinevskaMarija Dinevska
Marija Dinevska
LCLucero Cuzcano
Lucero Cuzcano
MPMichael Papanicolaou
Michael Papanicolaou
TCThomas R. Cox
Thomas R. Cox
TMTheo Mantamadiotis
Theo Mantamadiotis

12 January 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
YTYuqi Tan
Yuqi Tan
BKB.J. Kim
B.J. Kim
AMAdriana M. Mujal
Adriana M. Mujal
ACAlex C.Y. Chen
Alex C.Y. Chen
AWAllison M. Weis
Allison M. Weis
NHNir Hacohen
Nir Hacohen
The transition from trainee to independent investigator is one of the most challenging and formative phases of a scientific career. It requires not only scientific expertise but also the skills to lead, mentor, manage, and communicate effectively. The Arthur and Sandra Irving Cancer Immunology Symposium serves as a platform for established investigators to mentor trainees and early-career faculty as they navigate this transition to independence. Through sharing personal experiences and lessons from their own careers, senior leaders provide guidance on the scientific, professional, and personal challenges that shape a successful career in cancer immunology—emphasizing how curiosity, persistence, and a translational mindset can make a lasting real-world impact. This commentary highlights key themes, including leadership, communication, recruitment, and fundraising. Altogether, these insightful thoughts provide a framework for the next generation of cancer immunologists as they establish their independent careers as future leaders in the field.

2 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SWSamuel Stefanus Widodo
Samuel Stefanus Widodo
Marija DinevskaMarija Dinevska
Marija Dinevska
LCLucero Roxana Cuzcano
Lucero Roxana Cuzcano
MPMichael Papanicolaou
Michael Papanicolaou
TCThomas R. Cox
Thomas R. Cox
TMTheo Mantamadiotis
Theo Mantamadiotis
Metastatic cancer is responsible for the overwhelming majority of cancer-related deaths with metastatic tumors being the most common neoplasms affecting the central nervous system. One of the major factors regulating tumor biology is the tumor microenvironment. However, little is known about the cellular and non-cellular composition of metastatic brain tumors and how tumor cell ontogeny influences the metastatic brain tumor microenvironment. By integrating multiplex immunohistochemistry and histopathological analysis to investigate composition and the spatial relationship between neoplastic cells, infiltrating and brain resident immune cells and the extracellular matrix, we demonstrate that metastatic brain tumors exhibit differences in ECM deposition, compared with the most common primary brain tumor type, glioblastoma, and that the dominant immune cell types in metastatic brain tumors are immunosuppressive macrophages, which preferentially localize to ECM-rich stromal regions.